Otsuka : Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd. (125KB)
December 11, 2019 at 03:21 am EST
Share
For Immediate Release
December 11, 2019
Company name
Otsuka Holdings Co., Ltd.
Representative
Tatsuo Higuchi
President and Representative Director, CEO
Code number
4578 First Section, Tokyo Stock Exchange
Inquiries
Yuji Kogure
Director, Investor Relations Department
Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd. and its subsidiary Otsuka Pharmaceutical Co., Ltd. announce that the changes described below have been made to the composition of company officers at Otsuka Pharmaceutical, pursuant to decisions by the boards of directors at Otsuka Holdings and at Otsuka Pharmaceutical on December 11 and December 9, respectively.
The change of company officers will be decided formally at the general shareholders meeting of Otsuka Pharmaceutical on March 10, 2020, and the subsequent board meeting.
Particulars
Details on role changes
Name
:
Tatsuo Higuchi
New title
:
Chairman, Otsuka Pharmaceutical Co., Ltd.
Effective date
：
March 10, 2020
Current title
：
President and Representative Director, Otsuka Pharmaceutical Co., Ltd.
Name
：
Makoto Inoue
New title
：
President and Representative Director, Otsuka Pharmaceutical Co., Ltd.
＊Tatsuo Higuchi serves concurrently as president and representative director, CEO of Otsuka Holdings
-1-
Attachments
Original document
Permalink
Disclaimer
Otsuka Holdings Co. Ltd. published this content on 11 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 December 2019 08:20:06 UTC
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
